Regeneron Pharmaceuticals Inc. buy Guggenheim
Summary
This prediction is currently active. The BUY prediction by Guggenheim is currently unchanged from the start price. This prediction currently runs until 02.08.25. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w |
---|---|
Regeneron Pharmaceuticals Inc. | 0.00% |
iShares Core DAX® | -3.935% |
iShares Nasdaq 100 | -3.608% |
iShares Nikkei 225® | -4.513% |
iShares S&P 500 | -2.607% |
Comments by Guggenheim for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Guggenheim for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
19.07.24
19.07.25
02.08.24